Sagimet Biosciences (SGMT) – Market Overview and Recent Developments
Market Performance (24‑Hour Period Ending 07:44 PM CET, Friday 23 Nov 2026)
- Closing Price: USD 9.58 per share.
- Price Change: Up 2.57 %.
- Trading Volume: USD 15.8 million of shares exchanged, representing 70.3 million shares outstanding.
- Market Capitalisation: USD 705.5 million.
- Simple Moving Average (200 days): USD 7.35.
- 52‑Week High: USD 11.45 (recorded 10 Sept 2026).
- 52‑Week Low: USD 4.50 (recorded 30 Mar 2026).
- Month‑End Performance: Down 9.92 % compared with the previous month’s close.
Recent Corporate Announcement Sagimet Biosciences announced that the first patient has been dosed in the U.S. AURORA Phase 3 trial of denifanstat, a once‑daily fatty‑acid‑synthase (FASN) inhibitor, has begun. The trial is designed to enroll approximately 800 patients with moderate to severe acne. Data from this study will support a potential U.S. New Drug Application (NDA), with topline results expected in the second half of 2027.
Previous Phase 3 studies conducted in China by Sagimet’s license partner Ascletis achieved all primary and secondary endpoints and demonstrated a favorable safety profile, including a 52‑week open‑label extension. Sagimet highlighted the potential to provide a novel mechanism of action for a condition affecting roughly 10 million U.S. patients. The announcement followed an SEC filing that updated the company’s investor presentation and confirmed the progress of the U.S. trial.
Related Stock Activity (Last 24 Hours)
| Ticker | Recent Change | Current Price (USD) | Market Capitalisation (USD mn) | Key Corporate Update |
|---|---|---|---|---|
| SXC | –1.82 % | 9.86 | 839.4 | No new information reported. |
| ABUS | +0.72 % | 4.20 | 828.1 | FDA removed clinical hold on AB‑101; company may continue U.S. development. |
| CEVA | –5.31 % | 28.44 | 838.4 | Analyst coverage shift post‑earnings; mixed consensus on ratings. |
| AHCO | 0 % | 5.97 | 831.7 | No new information reported. |
| CRVS | +5.97 % | 10.39 | 845.4 | No new information reported. |
Company Profile – Sagimet Biosciences Inc.
- Headquarters: San Mateo, United States.
- Business Focus: Development of FASN inhibitors for non‑alcoholic steatohepatitis (NASH), acne, and oncology indications.
- Public Listing: Nasdaq, ticker SGMT.
- Initial Public Offering: 13 July 2023.
- Website: www.sagimet.com .
The company continues to advance its pipeline with a focus on dermatology and liver disease, supported by ongoing clinical trials and strategic partnerships.
